{"id":26119,"date":"2025-09-06T08:53:02","date_gmt":"2025-09-05T23:53:02","guid":{"rendered":"https:\/\/hic.lne.st\/?p=26119"},"modified":"2025-09-06T08:57:38","modified_gmt":"2025-09-05T23:57:38","slug":"%e3%80%90%e8%b6%85%e7%95%b0%e5%88%86%e9%87%8e%e5%ad%a6%e4%bc%9a-%e6%9d%b1%e4%ba%ac2026%e3%80%91%e5%9f%ba%e8%aa%bf%e8%ac%9b%e6%bc%94%e3%81%ab%e6%a0%aa%e5%bc%8f%e4%bc%9a%e7%a4%berhelixa%e4%bb%a3","status":"publish","type":"post","link":"https:\/\/hic.lne.st\/en\/2025\/09\/26119\/","title":{"rendered":"Rhelixa, Inc. and Ryu Nakaki will deliver the keynote lecture, \"Epigenome Analysis Opens a New Era of Personalized Anti-Aging\" on March 6, 2026, from 13:30 to 13:50."},"content":{"rendered":"<div class=\"vc_row wpb_row td-pb-row\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<p><span style=\"font-weight: 400\">Liberace, Inc. will be held in March 2026.<a href=\"https:\/\/hic.lne.st\/en\/schedule\/tokyo2026\/\">Hyper Interdisciplinary Conference Tokyo 2026<\/a>(Head Office: Chuo-ku, Tokyo; hereinafter \"Rhelixa\") as a keynote speaker.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Mr. Nakaki said,<\/span><span style=\"font-weight: 400\">Focusing on epigenomics since the beginning of his graduate research, he founded Rhelixa in 2015. Rhelixa is developing support services for omics research based on its unique epigenome analysis technology, and continues to take on the challenge of delivering scientific knowledge of epigenomics to society in a variety of forms, from support for basic research to medical and social implementation.<\/span><\/p>\n<p><span style=\"font-weight: 400\">In his presentation, Rhelixa will provide<\/span><a href=\"https:\/\/epiclock.jp\/\"><span style=\"font-weight: 400\">EpiClock\" biological age measurement test<\/span><span style=\"font-weight: 400\">\u00ae<\/span><span style=\"font-weight: 400\">\"<\/span><\/a><span style=\"font-weight: 400\">The presentation will introduce the research background, technology, and scientific credibility of the \"Mere Old Man\" and its social implementation through co-creation with medical care, government, and business, and will discuss \"the age when individual aging can be quantified.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Rhelixa was founded in 2015 based on the technological potential of \"epigenome analysis,\" which was the research theme of founder Mr. Nakaki during his graduate school days. From the very beginning of the company's foundation, its approach to social implementation based on a deep understanding of the technology by scientists themselves resonates deeply with the philosophy of Leave a Nest Co., Ltd., which is \"to realize the development of science and technology and to contribute to the global community.<\/span><\/p>\n<p><span style=\"font-weight: 400\">In 2024, the epigenome Facing Aging and Life Improvement through a New Approach of Measuring Age<\/span><a href=\"https:\/\/lne.st\/2024\/02\/14\/epiclock\/\"><span style=\"font-weight: 400\">epic clock<\/span><span style=\"font-weight: 400\">\u00ae<\/span><span style=\"font-weight: 400\">Co-launched the<\/span><\/a><span style=\"font-weight: 400\">EpiClock<\/span><span style=\"font-weight: 400\">\u00ae<\/span><span style=\"font-weight: 400\">We have continuously cooperated as an operating partner in co-creation projects, building contacts with medical institutions, food companies, and others together to help accelerate social implementation.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Rhelixa has been continuously developing its contract analysis business for universities and research institutions since 2015, and to date has conducted a cumulative total of approximately 13,000 support projects for 572 private companies and 368 universities and other research institutions (including approximately 700 support projects related to epigenome analysis)[1 ]. Our analysis technologies have been used in papers and reports by universities, medical institutions, and researchers in Japan and abroad[2], and we have a high degree of reliability, a proven track record, and an established reputation for our analysis technologies.<\/span><\/p>\n<p><span style=\"font-weight: 400\">EpiClock\u00ae is a model for predicting biological age (epigenetic clock) designed specifically for the characteristics of the Japanese population. Its development uses Rhelixa's proprietary transfer learning method called Transfer Elastic Net (TENet) [3]\ufffc. This method enables the construction of highly accurate models that reflect the epigenomic (DNA methylation) patterns of the Japanese population. The EpiClock\u00ae models constructed with this method have been established as models with high suitability and utility for the Japanese population, with the prediction error (RMSE) for biological age for the Japanese population reduced by approximately 17-661 TP3T and the correlation coefficient (PCC) increased by +0.012 to +0.026 points for all models compared to representative models developed overseas [4]. The PCC (correlation coefficient) increased by +0.012 to +0.026 points for all models, establishing it as a model with high suitability and utility for Japanese [5].<\/span><\/p>\n<p><span style=\"font-weight: 400\">As of August 2025, epic clock<\/span><span style=\"font-weight: 400\">\u00ae<\/span><span style=\"font-weight: 400\">has been introduced in approximately 140 medical institutions and clinics nationwide. In addition, 27 companies from a wide range of industries, including food, housing, and pharmaceuticals, are participating as co-creation partners in EpiClock<\/span><span style=\"font-weight: 400\">\u00ae<\/span><span style=\"font-weight: 400\">A \"co-creation project\" is also underway [6], from which seven projects are underway.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Several joint research projects with universities and research institutions are in progress, including a joint research project with Kyoto Prefectural University of Medicine. In these joint studies, EpiClock\u00ae is being used to \"visualize aging\" in an attempt to scientifically evaluate the aging of Japanese people and to narrow down lifestyle habits and factors that are key to healthy longevity [7].<\/span><\/p>\n<p><span style=\"font-weight: 400\">Through these clinical and community partnerships, EpiClock\u00ae is developing into a technology that is \"trusted and used\" both scientifically and socially.<\/span><\/p>\n<p><span style=\"font-weight: 400\">This keynote speech is positioned as the culmination of the \"co-creation journey\" between Rhelixa, which has continued to take on the challenge of connecting science and society, and LIVERNESS, which has supported it.<\/span><\/p>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div><\/div><\/div><\/div><div class=\"vc_row wpb_row td-pb-row\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\"><div class=\"vc_btn3-container vc_btn3-center\" >\r\n\t<a class=\"vc_general vc_btn3 vc_btn3-size-md vc_btn3-shape-rounded vc_btn3-style-modern vc_btn3-color-danger\" href=\"https:\/\/hic.lne.st\/en\/schedule\/tokyo2026\/\" title=\"\">Hyperdifferential Conference Tokyo 2026 Details<\/a><\/div>\r\n<\/div><\/div><\/div><\/div><div class=\"vc_row wpb_row td-pb-row\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<p><span style=\"font-weight: 400\">Keynote Speech Summary<\/span><\/p>\n<p><span style=\"font-weight: 400\">Conference Name: Japan Society for Hyperdifferent Fields Tokyo 2026<br \/>\n<\/span><span style=\"font-weight: 400\">Website:<\/span><a href=\"https:\/\/hic.lne.st\/en\/schedule\/tokyo2026\/\"><span style=\"font-weight: 400\">https:\/\/hic.lne.st\/schedule\/tokyo2026\/<\/span><\/a><br \/>\n<span style=\"font-weight: 400\">Speaker: Mr. Ryu Nakaki (President, Rhelixa Corporation)<br \/>\n<\/span><span style=\"font-weight: 400\">Title: Epigenome Analysis Opens a New Era of Personal Anti-Aging<br \/>\n<\/span><span style=\"font-weight: 400\">Date: Friday, March 6, 2026<br \/>\n<\/span><span style=\"font-weight: 400\">Venue: Bellesalle Shinjuku Grand Conference Center<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><span style=\"font-weight: 400\">(Sumitomo Fudosan Shinjuku Grand Tower 5F, 8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo)<br \/>\n<\/span><span style=\"font-weight: 400\">Organized by: Liverness Co.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Notes and reference links<\/span><\/p>\n<p><span style=\"font-weight: 400\">[1] Available on the company's website <\/span><a href=\"https:\/\/www.rhelixa.com\/service\/\"><span style=\"font-weight: 400\">https:\/\/www.rhelixa.com\/service\/<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><\/a><span style=\"font-weight: 400\">[2] 107 peer-reviewed papers published through 2024 (including 13 co-authored papers, 77 in Materials &amp; Methods, and 17 in Acknowledgements)<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><span style=\"font-weight: 400\">[3] Patent pending: Patent Application 2024-074544, see company website for an overview of the model structure.<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><span style=\"font-weight: 400\">[4] Horvath. Genome Biol. 2013. Hannum. Mol Cell. 2013.Levine. Aging (Albany NY). 2018.<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><span style=\"font-weight: 400\">[5] Transfer Elastic Net for Developing Epigenetic Clocks for the Japanese Population Tomo &amp; Nakaki. Mathematics. 2024.<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><span style=\"font-weight: 400\">[6] Available on the company's website <\/span><a href=\"https:\/\/epiclock.jp\/co-creation\/\"><span style=\"font-weight: 400\">https:\/\/epiclock.jp\/co-creation\/<\/span><span style=\"font-weight: 400\"><br \/>\n<\/span><\/a><span style=\"font-weight: 400\">[7] Available on the company's website <\/span><a href=\"https:\/\/www.rhelixa.com\/newsrelease-20251017\/\"><span style=\"font-weight: 400\">https:\/\/www.rhelixa.com\/newsrelease-20251017\/<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">About Rhelixa Corporation<\/span><\/p>\n<p><span style=\"font-weight: 400\">Company name: Rhelixa Inc.<\/span><a href=\"https:\/\/www.rhelixa.com\/\"><span style=\"font-weight: 400\">https:\/\/www.rhelixa.com\/<\/span><\/a><span style=\"font-weight: 400\">)<br \/>\n<\/span><span style=\"font-weight: 400\">Headquarters: KDX Ginza East Building 5F, 3-7-2 Irifune, Chuo-ku, Tokyo 104-0042, Japan<br \/>\n<\/span><span style=\"font-weight: 400\">Established: February 2015<br \/>\n<\/span><span style=\"font-weight: 400\">Representative Director: Ryu Nakaki<br \/>\n<\/span><span style=\"font-weight: 400\">Capital: 589 million yen (including capital reserve)<br \/>\n<\/span><span style=\"font-weight: 400\">Number of employees: 47 (including 15 Ph.)<br \/>\n<\/span><span style=\"font-weight: 400\">Business activities: Contract omics analysis and consulting services, development and operation of cloud services to support medical biology research, and provision of research, development and services related to anti-aging.<\/span><\/p>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div><\/div><\/div><\/div><div class=\"vc_row wpb_row td-pb-row\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div class=\"wpb_text_column wpb_content_element  vc_custom_1638493502226\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<h3 style=\"text-align: center\">speaker<\/h3>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<div class=\"vc_row wpb_row vc_inner td-pb-row vc_custom_1638493649958\"><div class=\"wpb_column vc_column_container td-pb-span4\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div  class=\"wpb_single_image wpb_content_element vc_align_right\">\r\n\t\t\r\n\t\t<figure class=\"wpb_wrapper vc_figure\">\r\n\t\t\t<div class=\"vc_single_image-wrapper vc_box_rounded  vc_box_border_grey\"><img width=\"212\" height=\"300\" src=\"https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-212x300.jpg\" class=\"vc_single_image-img attachment-medium\" alt=\"\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-212x300.jpg 212w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-8x12.jpg 8w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-71x100.jpg 71w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-150x212.jpg 150w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-198x280.jpg 198w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa-297x420.jpg 297w, https:\/\/hic.lne.st\/wp-content\/uploads\/sites\/37\/2025\/09\/d39ff028529e3017ca977067e201bbfa.jpg 395w\" sizes=\"(max-width: 212px) 100vw, 212px\" \/><\/div>\r\n\t\t<\/figure>\r\n\t<\/div>\r\n<\/div><\/div><\/div><div class=\"wpb_column vc_column_container td-pb-span8\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<p><strong>Mr. Ryu Nakaki<\/strong><br \/>\nPresident and Representative Director, Rhelixa Corporation<\/p>\n<p><span style=\"font-weight: 400\">D. in Engineering from the University of Tokyo. D. (Engineering).<\/span><\/p>\n<p><span style=\"font-weight: 400\">He is a computational biologist with a degree in Genome Science from the University of Tokyo's Research Center for Advanced Science and Technology, specializing in the development and application of algorithms for the analysis of whole genome and epigenome data.<\/span><\/p>\n<p><span style=\"font-weight: 400\">He has published several methodologies on analysis techniques developed by himself and has been involved in numerous omics research projects and has been extensively involved in academic publications as a co-author.<\/span><\/p>\n<p><span style=\"font-weight: 400\">In 2015, he founded Rhelixa, Inc. to support omics research. Since its inception, the company has supported over 13,000 research projects and is currently developing a biological age measurement technology, EpiClock<sup>\u00ae<\/sup>He is leading the research and development of the \"Mere Old Man\" and social implementation projects with medical, corporate, and local governments.<\/span><\/p>\n<p><span style=\"font-weight: 400\">As a councilor of the Japanese Society of Anti-Aging Medicine and a visiting researcher at the University of Tokyo's Graduate School of Engineering, he also contributes to the field of aging research and preventive medicine. As a practitioner of co-creative research linking science and society, he is pioneering new possibilities in aging, wellness, and life course medicine.<\/span><\/p>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div><\/div><\/div><\/div>\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<h3 style=\"text-align: center\">Registration for auditing and participation is now open.<\/h3>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<p style=\"text-align: center\">We look forward to welcoming many people from academia, venture companies, large corporations, local medium-sized and small companies, local factories, producers, local governments, junior high and high school students, and technical college students to the Hyperdifferent Field Conference.<\/p>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div><\/div><\/div><\/div><div class=\"vc_row wpb_row td-pb-row\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\"><div class=\"vc_btn3-container vc_btn3-center\" >\r\n\t<a class=\"vc_general vc_btn3 vc_btn3-size-md vc_btn3-shape-rounded vc_btn3-style-modern vc_btn3-color-danger\" href=\"https:\/\/hic.lne.st\/en\/schedule\/tokyo2026\/\" title=\"\">Click here to register your abstract or attend the lecture.<\/a><\/div>\r\n<\/div><\/div><\/div><\/div><div class=\"vc_row wpb_row td-pb-row vc_custom_1638494157404\"><div class=\"wpb_column vc_column_container td-pb-span12\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\">\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<h3 style=\"text-align: center\">Contact Us<\/h3>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"wpb_text_column wpb_content_element\" >\r\n\t\t<div class=\"wpb_wrapper\">\r\n\t\t\t<p>For inquiries regarding this matter, please contact<\/p>\n<p>Liverness Corporation (Nakajima, Seno)<br \/>\nTEL: 03-5227-4198<br \/>\ne-mail : RD@lnest.jp<\/p>\n\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"Liverness Corporation is pleased to announce that Mr. Ryu Nakagi, President of Rhelixa Corporation (Headquartered in Chuo-ku, Tokyo; hereinafter referred to as \"Rhelixa\"), will be the keynote speaker at the Super-Different Field Conference Tokyo 2026, to be held in March 2026 [...].","protected":false},"author":47,"featured_media":26130,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","footnotes":""},"categories":[99],"tags":[],"year_conference":[96,95],"acf":[],"aioseo_notices":[],"modified_by":"\u585a\u7530\u5468\u5e73","_links":{"self":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/26119"}],"collection":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/comments?post=26119"}],"version-history":[{"count":6,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/26119\/revisions"}],"predecessor-version":[{"id":26137,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/26119\/revisions\/26137"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/media\/26130"}],"wp:attachment":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/media?parent=26119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/categories?post=26119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/tags?post=26119"},{"taxonomy":"year_conference","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/year_conference?post=26119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}